Hinke Siebinga
0000-0001-7767-0393
Netherlands Cancer Institute
10 papers found
Refreshing results…
The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients
A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE
Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough
The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer
A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors
Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections
Missing publications? Search for publications with a matching author name.